Abstract B022: The polyaneuploid transition as a hedge against failures in resistance acquisition
Authors: George Butler, Julia Bos, Robert H. Austin, Sarah R. Amend, Kenneth J. Pienta
Journal: Cancer Research (2022)

Abstract Metastatic cancer is incurable because tumors evolve resistance to all classes of therapy, resulting the in the deaths of 10 million people each year. Therapy resistance is typically attributed to the presence of a cancer stem cell or genetic tumor cell heterogeneity. However, therapeutic resistance can also emerge through a transient cell state: the Polyaneuploid Cancer Cell (PACC) state. The Polyaneuploid transition (PAT) is an evolutionary conserved polyploid program accessed by cancer cells in response to an external stress such as chemotherapy. Once the stress subsides, cells exit the PACC state and repopulate a non-polyploid population that is resistant to multiple classes of therapy. We hypothesize that the PAT facilitates inherited universal therapeutic resistance. We utilized the bacteria E. coli as a model system of the evolutionary conserved polyploid mechanism of resistance. The E. coli strain MG1655 was engineered to express an hupA::GFP reporter to monitor nucleoid DNA or a ibpA::GFP reporter to monitor the aggregation of misfolded proteins. We treated these cultures with ciprofloxacin at near lethal doses for 12 hours and recorded the dynamics with fluorescent time-lapse microscopy. Individual bacteria underwent a transient phase of polyploidization causing an elongated filamentous phenotype that is at least an order of magnitude bigger compared to the unstressed bacteria. During filamentation, we found that the misfolded protein aggregates are shuttled along the cell body to the tips. Eventually, the filaments bud resulting in a population of “typical” length cells. The buds that are produced by the filaments are filled with an excess of misfolded protein aggregate and, surprisingly, are commonly void of DNA. This response is unexpected in a cell that is already resistant due to the high fitness cost. However, if the cell is not resistant, then each misfolded protein may represent an attempt to solve the antibiotic puzzle and to achieve a resistant phenotype. In turn, the ability to efficiently collect and dispose of the misfolded proteins, i.e., the previous failed attempt, may be advantageous to reduce the need for protein degradation and ensure that future protein production is not impaired. Taken together, this finding suggests that antibiotic resistance might be dependent on the ability to endure repeated futile endeavors to explore the phenotypic landscape rather than selecting for individuals that already exist at an evolutionary optimum. As a result, the PAT may act as a buffer by which cancer cells “buy time” to search within the phenotypic landscape and look for a path to resistance. Future work will specifically test this model in cancer cells. If true, then this finding would suggest that therapeutic resistance can be actively delayed by inhibiting the PAT during first line treatment. Citation Format: George Butler, Julia Bos, Robert H. Austin, Sarah R. Amend, Kenneth J. Pienta. The polyaneuploid transition as a hedge against failures in resistance acquisition [abstract]. In: Proceedings of the AACR Special Conference on the Evolutionary Dynamics in Carcinogenesis and Response to Therapy; 2022 Mar 14-17. Philadelphia (PA): AACR; Cancer Res 2022;82(10 Suppl):Abstract nr B022.